These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 6769666)

  • 1. Meal-dependent absorption of enteric-coated sodium valproate.
    Levy RH; Cenraud B; Loiseau P; Akbaraly R; Brachet-Liermain A; Guyot M; Gomeni R; Morselli PL
    Epilepsia; 1980 Jun; 21(3):273-80. PubMed ID: 6769666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.
    Marcelín-Jiménez G; Angeles-Moreno AP; Contreras-Zavala L; Morales-Martínez M; Rivera-Espinosa L
    Clin Ther; 2009 Sep; 31(9):2002-11. PubMed ID: 19843490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-dose kinetics and bioavailability of sodium-hydrogen divalproate.
    Anderson P; Elwin CE
    Clin Neuropharmacol; 1985; 8(2):156-64. PubMed ID: 3924399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of food on the serum concentration profile of enteric-coated valproic acid.
    Fischer JH; Barr AN; Paloucek FP; Dorociak JV; Spunt AL
    Neurology; 1988 Aug; 38(8):1319-22. PubMed ID: 3135514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative absorption profiles of divalproex sodium delayed-release versus extended-release tablets -- clinical implications.
    Dutta S; Reed RC; O'Dea RF
    Ann Pharmacother; 2006 Apr; 40(4):619-25. PubMed ID: 16569797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of valproic acid obtained after administration of three oral formulations to humans.
    Bialer M; Hussein Z; Dubrovsky J; Raz I; Abramsky O
    Isr J Med Sci; 1984 Jan; 20(1):46-9. PubMed ID: 6421770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioavailability of a film-coated tablet of valproate in nonfasting volunteers.
    Ishikawa T; Horie M; Furuyama M; Ohuchi M; Awaya A; Sobajima H; Suchi M; Yamaguchi A; Okajima K; Wanibe M
    Jpn J Psychiatry Neurol; 1987 Dec; 41(4):693-8. PubMed ID: 3134567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absorption characteristics of a new valproate formulation: divalproex sodium-coated particles in capsules (Depakote Sprinkle).
    Carrigan PJ; Brinker DR; Cavanaugh JH; Lamm JE; Cloyd JC
    J Clin Pharmacol; 1990 Aug; 30(8):743-7. PubMed ID: 2119396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bioavailability of a valproic acid preparation. The relative bioavailability of enteric-resistant valproic acid preparations in tablet form with simultaneously administered tetradeuterated valproic acid as the bioavailability reference].
    Hoffmann F; Jancik BC; von Unruh GE
    Arzneimittelforschung; 1986 Jul; 36(7):1118-22. PubMed ID: 3094548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and bioavailability of sodium valproate.
    Klotz U; Antonin KH
    Clin Pharmacol Ther; 1977 Jun; 21(6):736-43. PubMed ID: 324695
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of food on the absorption and pharmacokinetics of prednisolone from enteric-coated tablets.
    Al-Habet SM; Rogers HJ
    Eur J Clin Pharmacol; 1989; 37(4):423-6. PubMed ID: 2598978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absolute bioavailability and absorption characteristics of divalproex sodium extended-release tablets in healthy volunteers.
    Dutta S; Reed RC; Cavanaugh JH
    J Clin Pharmacol; 2004 Jul; 44(7):737-42. PubMed ID: 15199078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic characteristics of a new multiple unit sustained release formulation of sodium valproate.
    Wangemann M; Retzow A; Vens-Cappell B
    Int J Clin Pharmacol Ther; 1999 Feb; 37(2):100-8. PubMed ID: 10082174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative steady state serum levels of valproic acid administered as two different formulations--Deprakine and Orfiril.
    Johannessen SI; Henriksen O
    Acta Neurol Scand; 1979 Dec; 60(6):371-4. PubMed ID: 121513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacokinetic study of sodium di-n-propylacetate (usual tablet and enteric coated tablet with delayed absorption) (author's transl)].
    van de Mortel I; franck G
    Acta Neurol Belg; 1976; 76(3):165-72. PubMed ID: 788439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of enteric-coated valproic acid.
    Albright PS; Bruni J; Suria D
    Ther Drug Monit; 1984; 6(1):21-3. PubMed ID: 6424275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disposition of valproic acid in man.
    Gugler R; Schell A; Eichelbaum M; Fröscher W; Schulz HU
    Eur J Clin Pharmacol; 1977 Oct; 12(2):125-32. PubMed ID: 336377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of a high-fat meal on the bioavailability of a polymer-coated erythromycin particle tablet formulation.
    Randinitis EJ; Sedman AJ; Welling PG; Kinkel AW
    J Clin Pharmacol; 1989 Jan; 29(1):79-84. PubMed ID: 2708552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioavailability of valproic acid under fasting/nonfasting regimens.
    Chun AH; Hoffman DJ; Friedmann N; Carrigan PJ
    J Clin Pharmacol; 1980 Jan; 20(1):30-6. PubMed ID: 6766956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epilim chrono: a multidose, crossover comparison of two formulations of valproate in healthy volunteers.
    Roberts D; Easter D; O'Bryan-Tear G
    Biopharm Drug Dispos; 1996 Mar; 17(2):175-82. PubMed ID: 8907724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.